FDA up­dates Gilead­'s la­bel for CAR-T Tecar­tus with new boxed warn­ing for sec­ondary can­cer

The FDA on Mon­day pulled but then up­dat­ed and pub­lished a new let­ter to Gilead ad­vis­ing that its CAR-T drug Tecar­tus does need a boxed warn­ing for sec­ondary can­cer, reaf­firm­ing that this is a class-wide risk in the eyes of the reg­u­la­to­ry agency.

Last week, the FDA told No­var­tis, Gilead, Bris­tol My­ers Squibb and John­son & John­son to add boxed warn­ings on the la­bels of all six cur­rent­ly mar­ket­ed CAR-T ther­a­pies. At the first pub­li­ca­tion, five of the six let­ters had warn­ings that said T cell ma­lig­nan­cies “have oc­curred fol­low­ing treat­ment with BC­MA- and CD19- di­rect­ed ge­net­i­cal­ly mod­i­fied au­tol­o­gous T cell im­munother­a­pies.”

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

Vice President

Alexandria Real Estate Equities

San Francisco, CA, USA